In the 25 years since the company’s launch, she estimates that LSBio has performed IHC testing on more than 80,000 antibodies and she has personally evaluated more than 25,000 different ...

Roche’s PATHWAY HER2 (4B5) test helps identify patients with HER2-ultralow breast cancer, who may be eligible for targeted ...

The agency approved the drug based on data from the DESTINY-Breast06 trial, which included patients who had tumors with very low HER2 expression.

AstraZeneca and Daiichi Sankyo’s Enhertu (trastuzumab deruxtecan) has been approved in the US for the treatment of adult patients with unresectable or metastatic hormone receptor (HR)-positive, ...

AstraZeneca and Daiichi Sankyo's Enhertu (trastuzumab deruxtecan) has been approved in the US for the treatment of adult ...

New approval brings the medicine to an earlier treatment setting and a broader patient population.

The Cambridge, England-based and Tokyo-based pharmaceutical companies said the US Food & Drug Administration approved Enhertu for the treatment of adult patients with unresectable or metastatic ...